

## **Malu Martinez Chantar**

*Liver Disease Lab, Center for Cooperative Research in Biosciences, Basque Research and Technology Alliance, Derio, **Spain***

### **Biographical sketch:**

I have an extensive experience in the study of liver biology with a high-level track of productivity in the 1<sup>st</sup> decile journals like Nature, Nature Communications, Cell Metabolism, Hepatology, Journal of Hepatology and Gastroenterology. Since 2005, when I initiated my laboratory as a Principal Investigator and got “tenure” at CIC bioGUNE, Spain, my laboratory has been continuously financially supported by government and private funding competitive sources, both national and international. Remarkably, I have been co-PI of NIH grants in the field of liver disease. I was one of the partners in an ambitious European project so called HEPADIP Consortium, which was created in response to the topic of the 3rd call for proposals in the EU FP6 Program. Actually, I am the coordinator of the Translational Area of the National Institute for the study of Liver and Gastrointestinal Diseases (CIBEREHD) and the Scientific Advisory Board of the Molecular Medicine Center C3M Nice and IDIVAL. My visibility in the liver field has been intensified through an extensive participation in different national and international networks such as Ciberehd, Women in Hepatology (International Consortium), Hepamet Registry, MetaboCancer Excellence Network and different European COST actions PROTEOSTASIS, TRANSAUTOPHAGY and MITOEAGLE.

I have also held several collaborations with Pharmaceutical companies with 7 resultant patent applications and 4 licensed products. Finally, I have maintained a closed collaboration with the company OWL Metabolomics in the development of OWLiver® Care and OWLiver®, two non-invasive assays for fatty liver screening and for NASH diagnosis.